TheraVet
TheraVet is a Belgian veterinary biotech that develops and commercializes injectable phosphocalcic (alpha-TCP) bone substitutes and related regenerative products for companion animals, sold through direct e-commerce and a 24-country distributor network to veterinary practices and specialty hospitals.
- Company typePrivate
- Founded2017
- HeadquartersGosselies, Belgium
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What TheraVet does
TheraVet S.A. is a Belgian veterinary biotechnology company headquartered in Gosselies (Wallonia, Belgium) that develops and commercializes biomaterial-based treatments for osteoarticular diseases in companion animals (dogs, cats, and horses). The company's core technology is a proprietary line of injectable, self-hardening phosphocalcic (alpha-tricalcium phosphate, alpha-TCP) bone void fillers marketed under the BIOCERA-VET brand, positioned as alternatives to autologous bone grafts that avoid the morbidity of a second surgical site. The commercial product family comprises BIOCERA-VET BONE SURGERY RTU for general orthopedic procedures (arthrodesis, fractures, corrective osteotomy, TTA), BIOCERA-VET GRANULES and BIOCERA-VET SMARTGRAFT for bone grafting, BIOCERA-VET OSTEOSARCOMA RTU for canine osteosarcoma, and BIOCERA-VET COMBO/COMBO-CLEAN, a local sustained-release antibiotic-releasing bone substitute launched in 2023. A pipeline product, VISCO-VET (intra-articular injectable gel based on hyaluronic acid, species-specific plasma and an active pharmaceutical component), targets osteoarthritis and remains under investigation without market authorization.
TheraVet makes money through B2B sales of BIOCERA-VET devices and consumables to veterinary practices and specialty hospitals, distributed via a mix of direct e-commerce (bioceravet.com) and an extensive partner network that includes an international agreement with Vetpharma covering 24 countries, alongside regional partners in Italy (Alcyon Italia), Spain (Nuzoa), France (Elvetis), the UK and Ireland (Veterinary Instrumentation) and an exclusive US distributor. The company has a wholly-owned US subsidiary to support North American operations. Customers are companion-animal veterinarians and referral hospitals performing orthopedic and oncologic surgery; pain points addressed include the limitations of conventional bone grafts (availability, donor-site pain, infection risk) and the lack of limb-sparing options for canine osteosarcoma patients. Market context is sizable — osteoarthritis reportedly affects more than 34 million dogs worldwide and cranial cruciate ligament deficiency affects over 4 million — but TheraVet itself is a sub-50-employee private firm that does not publicly disclose revenue, and the credibility of the financial figures supplied in the source material is highly questionable (orders of magnitude inconsistent with the firm's size).
TheraVet firmographics
Firmographics- Name
- TheraVet
- Legal name
- TheraVet S.A.
- Website
- https://thera.vet
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- TheraVet is a Belgian veterinary biotech that develops and commercializes injectable phosphocalcic (alpha-TCP) bone substitutes and related regenerative products for companion animals, sold through direct e-commerce and a 24-country distributor network to veterinary practices and specialty hospitals.
- Ownership category
- akta.pro rank
TheraVet industry classification
Industry- Product category
- Veterinary Orthopedic Products
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Orthopedic & Implantable Devices (Plates, Screws, TPLO, Prosthetics) (HLAMAFAE)
- akta.pro secondary industries
- Tissue Engineering & Biomaterial Scaffolds (HLAMANAC), Clinical Research, Trials & Translational Services (Veterinary Regenerative) (HLAMANAL)
Keywords
Where TheraVet is headquartered
LocationHeadquarters
- HQ city
- Gosselies
- HQ country
- Belgium
- HQ region
- Europe
Offices2 records
Markets served
TheraVet business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- BIOCERA-VET Product Sales: Sale of bone substitute products including BIOCERA-VET Bone Surgery RTU, BIOCERA-VET Granules, BIOCERA-VET Smartgraft, BIOCERA-VET Osteosarcoma RTU, and BIOCERA-VET COMBO (antibiotic releasing bone substitute). Products are sold through direct e-commerce and distribution partners.
Go-to-market motion1 record
Distribution channels7 records
Marketing channels7 records
TheraVet product offering
Product offeringCore offering
TheraVet develops and commercializes BIOCERA-VET, a proprietary line of injectable, self-hardening phosphocalcic (alpha-tricalcium phosphate) bone void fillers for veterinary orthopedic applications. The products are designed for bone surgery, fracture repair, osteosarcoma palliative treatment, and bone grafting in companion animals (dogs, cats, horses), and are sold through direct e-commerce and veterinary distributors across Europe and the United States.
Product overview
TheraVet is a vet biotech company offering a portfolio of bone substitute products under the BIOCERA-VET brand for companion animals (dogs, cats, and horses). The product line includes BIOCERA-VET BONE SURGERY RTU (ready-to-use injectable bone substitute for general orthopedic surgery), BIOCERA-VET GRANULES (granular bone graft formulation), BIOCERA-VET SMARTGRAFT (biological bone grafts), and BIOCERA-VET OSTEOSARCOMA RTU (specialized formulation for osteosarcoma treatment). Additional products include BIOCERA-VET COMBO and BIOCERA-VET COMBO-CLEAN (antibiotic-releasing bone substitutes). The company also has VISCO-VET, an intra-articular injectable gel based on hyaluronic acid and plasma, in its pipeline for osteoarthritis treatment.
Differentiator
Problem solved
Functional benefit
Brands
- BIOCERA-VET BONE SURGERY RTU: Injectable self-hardening phosphocalcic bone void filler for bone surgery applications
- BIOCERA-VET GRANULES
- BIOCERA-VET SMARTGRAFT
- BIOCERA-VET OSTEOSARCOMA RTU
- BIOCERA-VET COMBO-CLEAN
- VISCO-VET
Products and services
- BIOCERA-VET The full range of injectable self-hardening phosphocalcic bone void fillers with enhanced osteointegration, osteoinduction and bone remodeling properties for veterinary orthopedic applications in companion animals.
- BIOCERA-VET BONE SURGERY RTU Ready-to-use injectable bone substitute for bone surgery applications including arthrodesis, fractures, corrective osteotomy, and TTA procedures in dogs and cats.
- BIOCERA-VET GRANULES Granular bone graft substitute formulation within the BIOCERA-VET product line for veterinary orthopedic applications.
- BIOCERA-VET SMARTGRAFT Innovative line of biological bone grafts within the BIOCERA-VET portfolio for veterinary applications.
- BIOCERA-VET OSTEOSARCOMA RTU Ready-to-use bone substitute for palliative treatment of osteosarcoma in dogs, providing pain limitation and structural bone reinforcement.
- BIOCERA-VET COMBO / COMBO-CLEAN Local and sustained antibiotic releasing bone substitute combining bone void filling with antibiotic delivery capabilities for veterinary orthopedic applications.
Quantifiable outcome
- 300% increase in participating centers in Osteosarcoma Program within 6 months
- +1 more outcomes
Companies that use TheraVet
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles2 records
TheraVet technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
TheraVet partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered regional partner, clinical research partner, product development, key international partner, key strategic partner, key distribution partner, research partner and clinical partner.
- Alcyon Italiaregional partnerDistribution agreement for the BIOCERA-VET product line in Italy. Alcyon Italia distributes veterinary products and services in the Italian market.
- University of Floridaclinical research partnerLaunch of BIOCERA-VET Canine Osteosarcoma Study conducted by the University of Florida College of Veterinary Medicine.
- BIOCERA-VET COMBO Product Launchproduct developmentCommercial launch of BIOCERA-VET COMBO, a local and sustained antibiotic releasing bone substitute for veterinary orthopedic applications.
- Vetpharmakey international partnerInternational distribution agreement covering 24 countries for BIOCERA-VET products. Vetpharma is a veterinary pharmaceutical distribution network.
- US Distribution Partnerkey strategic partnerExclusive distribution agreement for BIOCERA-VET in the United States. Commercial launch announced June 30, 2022.
- Veterinary Instrumentationkey distribution partnerDistribution agreement for BIOCERA-VET in UK and Ireland. Veterinary Instrumentation is a specialist in orthopaedics and surgical instrumentation.
- Nuzoaregional partnerDistribution agreement for BIOCERA-VET in Spain. Nuzoa is a leading Spanish company in distribution of veterinary products and services.
- Elvetisregional partnerDistribution agreement for BIOCERA-VET range in France. Elvetis is a veterinary distribution company.
- INNOTEREresearch partnerResearch and distribution collaboration for BIOCERA-VET product line expansion. INNOTERE is a German company specializing in biomaterials.
- Ter Braakeclinical partnerPartnership for assessment of BIOCERA-VET in horse bone cyst treatment. Located in the Netherlands.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
TheraVet competitors and assessment
Company assessmentOthers
- INNOTERE: German biomaterials company specializing in calcium-phosphate-based bone cements and substitutes (and an existing TheraVet research/distribution partner) — directly comparable on biomaterial technology and an ecosystem participant.
Direct peers
- Kindred Biosciences: Veterinary biopharmaceutical company focused on developing biologic therapies for companion animals — comparable as a small-cap veterinary-biotech targeting chronic and osteoarticular conditions in dogs and cats.
- PetVivo Holdings: Veterinary medical device/biomaterials company marketing injectable implant products for osteoarthritis and orthopedic conditions in companion animals — closely comparable business model to TheraVet's injectable orthopedic biomaterials franchise.
- Aratana Therapeutics: Veterinary biotech (now operating under Elanco) that developed biologic therapeutics for companion animals, including osteoarthritis and pain indications — directly comparable to TheraVet's positioning as a veterinary-biotech developing biologic therapies for canine musculoskeletal diseases.
- VetStem Biologics: Veterinary regenerative medicine company offering stem-cell based therapies for osteoarthritis, tendon/ligament injuries and orthopedic indications in dogs, cats and horses — directly comparable to TheraVet's BIOCERA-VET bone-substitute and pipeline osteoarthritis play.
Broad incumbents
- Dechra Pharmaceuticals: Specialty veterinary pharmaceuticals company with a significant companion-animal endocrinology, dermatology and orthopedics portfolio — comparable as a European-headquartered specialty animal-health company overlapping with TheraVet's European distribution footprint.
- Zoetis: Largest global animal-health company with a broad portfolio across companion-animal pharmaceuticals, biologics and devices — comparable as a broad incumbent that competes with TheraVet in veterinary orthopedic and pain-management categories.
- Elanco Animal Health: Global animal-health company with a strong companion-animal portfolio including osteoarthritis and pain products (expanded via Aratana and KindredBio acquisitions) — comparable broad incumbent competing with TheraVet in canine orthopedics and OA.
- Vetoquinol: French-headquartered global veterinary pharmaceutical company with companion-animal therapeutic products including orthopedic and pain indications — comparable as a mid-sized European animal-health peer operating in overlapping categories.
- Virbac: Global veterinary pharmaceutical company headquartered in France with a broad companion-animal portfolio — comparable as a similarly sized European-rooted animal-health competitor active in canine orthopedics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
TheraVet social profiles
Digital presenceTheraVet compliance and trust
Trust signalCompliance1 record
TheraVet financial estimates
Financial estimateRevenue estimate
Valuation estimate
TheraVet leadership team
Management profileNumber of profiles
Profiles9 records
TheraVet subsidiaries and ownership
Company hierarchySubsidiaries1 record
TheraVet funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TheraVet M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TheraVet
What does TheraVet do?
TheraVet develops and commercializes BIOCERA-VET, a proprietary line of injectable, self-hardening phosphocalcic (alpha-tricalcium phosphate) bone void fillers for veterinary orthopedic applications. The products are designed for bone surgery, fracture repair, osteosarcoma palliative treatment, and bone grafting in companion animals (dogs, cats, horses), and are sold through direct e-commerce and veterinary distributors across Europe and the United States.
Is TheraVet a public or private company?
TheraVet is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was TheraVet founded?
TheraVet was founded in 2017. It employs 11 to 50 people.
Where is TheraVet based?
TheraVet is headquartered in Gosselies, Belgium, in the Europe region.
How does TheraVet make money?
One revenue line is on record: BIOCERA-VET Product Sales.
Who are TheraVet's main competitors?
INNOTERE is listed as an others. Direct peers are Kindred Biosciences, PetVivo Holdings, Aratana Therapeutics and VetStem Biologics. Broad incumbents are Dechra Pharmaceuticals, Zoetis, Elanco Animal Health, Vetoquinol and Virbac.
Does TheraVet have an API?
No public API is recorded for TheraVet.
What industry is TheraVet in?
TheraVet's product category is Veterinary Orthopedic Products. Its primary akta.pro industry code is HLAMAFAE, Orthopedic & Implantable Devices (Plates, Screws, TPLO, Prosthetics), with a secondary code of HLAMANAC, Tissue Engineering & Biomaterial Scaffolds. Its NAICS code is 325414 and its SIC code is 3842.